Classification of deprescribing and its use in an elderly patient with cognitive impairment

DOI: https://doi.org/10.29296/25877305-2021-06-16
Download full text PDF
Issue: 
6
Year: 
2021

G. Krasnov(1); Associate Professor S. Bulgakova(1), MD; Associate Professor E. Treneva(1),
Candidate of Medical Sciences; Professor N. Zakharova(1), MD; Associate Professor A. Nikolaeva(1), Candidate
of Medical Sciences; O. Rozhdestvenskaya(2), Candidate of Medical Sciences (1)Samara State Medical
University, Ministry of Health of Russia (2)Academy of Postgraduate Education, Federal Research and Clinical
Center, Federal Biomedical Agency of Russia, Moscow

Deprescribing antihypertensive agents is a planned or situational process of discontinuation, replacement, and dose reduction, which is adequately controlled by a physician. The paper considers a case of deprescribing using the STOPP/START criteria and expert evaluation in the hospital, and also provides a comparative assessment of the patient’s data at the hospital admission and before his discharge.
Keywords: 
deprescribing
polymorbidity
polypragmasia

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Sychev D.A. Polipragmazija v klinicheskoj praktike: problema i sposoby reshenija. Uchebnoe posobie, 2-e izd., ispr. i dop. SPb: TsOP «Professija», 2018; 272 s. [Sychev D.A. Polipragmaziya v klinicheskoi praktike: problema i sposoby resheniya. Uchebnoe posobie, 2-e izd., ispr. i dop. SPb: TsOP «Professiya», 2018; 272 p. (in Russ.)].
  2. Martin-Pérez M., López de Andrés A., Hernández-Barrera V. et al. Prevalence of polypharmacy among the population older than 65 years in Spain: Analysis of the 2006 and 2011/12 National Health Surveys. [Article in Spanish]. Rev Esp Geriatr Gerontol. 2017; 52 (1): 2–8. DOI: 10.1016/j.regg.2016.07.006
  3. Depreskrajbing ingibitorov protonnoj pompy u patsientov pozhilogo i starcheskogo vozrasta. Proekt protokola [Depreskraibing ingibitorov protonnoi pompy u patsientov pozhilogo i starcheskogo vozrasta. Proekt protokola (in Russ.)]. URL: https://rgnkc.ru/images/pdf_documets/Depreskraibing/Depreskraibing_2_0_1.pdf
  4. Fick D.M., Semla T.P., Steinman M. et al. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019; 67 (4): 674–94. DOI: 10.1111/jgs.15767
  5. O’Mahony D., O’Sullivan D., Byrne S. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2014; 44 (2): 213–8. DOI: 10.1093/ageing/afu145
  6. Pazan F., Weiss C., Wehling M. FORTA. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018; 35 (1): 61–71. DOI: 10.1007/s40266-017-0514-2
  7. Warlé-van Herwaarden M.F., Kramers C., Sturkenboom M.C. et al. Dutch HARM-Wrestling Task Force. Targeting outpatient drug safety: recommendations of the Dutch HARM-Wrestling Task Force. Drug Saf. 2012; 35 (3): 245–59. DOI: 10.2165/11596000-000000000-00000
  8. Koponen M., Taipale H., Lavikainen P. et al. Risk of mortality associated with antipsychotic monotherapy and polypharmacy among community-dwelling persons with Alzheimer’s disease. J Alzheimers Dis. 2017; 56: 107–18. DOI: 10.3233/JAD-160671
  9. Koponen M., Taipale H., Tanskanen A. et al. Long-term use of antipsychotics among community-dwelling persons with Alzheimers disease: A nationwide register-based study. Eur Neuropsychopharmacol. 2015; 25: 1706–13. DOI: 10.1016/j.euroneuro.2015.07.008
  10. Liperoti R., Sganga F., Landi F. et al. Antipsychotic drug interactions and mortality among nursing home residents with cognitive impairment. J Clin Psychiatry. 2017; 78: e76–e82. DOI: 10.4088/JCP.15m10303
  11. Pariente A., Fourrier-Reglat A., Ducruet T. et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med. 2012; 172 (8): 648–53. DOI: 10.1001/archinternmed.2012.28
  12. Proton Pump Inhibitors – How much for how long? URL: https://www.veteransmates.net.au/topic-32
  13. Garfinkel D., Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010; 170: 1648–54. DOI: 10.1001/archinternmed.2010.355
  14. Garfinkel D. Poly-de-prescribing to treat polypharmacy: efficacy and safety. Ther Adv Drug Saf. 2017; 9 (1): 25–43. DOI: 10.1177/2042098617736192